Appili Therapeutics Inc.
APLIF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | 0.01 | 0.01 | -0.01 |
| FCF Yield | 20.11% | -71.75% | -490.73% | -140.37% |
| EV / EBITDA | 42.64 | -5.60 | -0.27 | 0.08 |
| Quality | ||||
| ROIC | 17.43% | 80.42% | -452.37% | -171.44% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | -0.33 | 0.65 | 0.76 | 0.80 |
| Growth | ||||
| Revenue 3-Year CAGR | -33.01% | -15.89% | – | 91.15% |
| Free Cash Flow Growth | 134.74% | 86.93% | -66.54% | -168.90% |
| Safety | ||||
| Net Debt / EBITDA | 30.69 | -3.91 | 0.21 | 0.43 |
| Interest Coverage | -0.06 | -1.33 | -7.09 | -15.19 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 6,071.79 | 0.00 | 459.60 | 0.00 |